These data, along with the growth inhibition we observed in the FGFR2-amplified breast cancer models in our study, support the need to further explore the efficacy of FGFR inhibitors against tumors with high-level, clonal FGFR2 amplifications. This evidence concerns the gene FGFR2 and breast carcinoma.